– USA, MA – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, announced the appointment of Chip Clark to its board of directors.
About Chip Clark
Mr. Clark has more than three decades of leadership experience in the biopharmaceutical industry. He currently serves as Co-founder and CEO of Vibrant Biomedicines, a venture-backed company developing vaccines that target bacterial pathogens. Before co-founding Vibrant Biomedicines, Mr. Clark served as CEO of Genocea Biosciences, Inc. Before Genocea, he held the role of CBO at Vanda Pharmaceuticals Inc., a publicly traded biotechnology company he co-founded in 2004. Before his tenure at Vanda, Mr. Clark was a Principal at Care Capital, LLC, a venture capital firm focused on investments in biopharmaceutical companies. Mr. Clark began his career at SmithKline Beecham Corporation, now part of GlaxoSmithKline plc, where he spent 10 years in a range of management positions.
Chip Clark holds a Master of Business Administration from The Wharton School of the University of Pennsylvania and a Bachelor of Arts from Harvard University.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, to optimize multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
For more: https://www.aldeyra.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.